Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer

Background: In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied empirically to all patients. The aim of this study was to establish a multigene classifier of sensitivity to neoadjuvant FEC100. Materials a...

Full description

Saved in:
Bibliographic Details
Published inCancer genomics & proteomics Vol. 3; no. 2; p. 89
Main Authors MARIE MILLOUR, CATHERINE CHARBONNEL, FLORENCE MAGRANGEAS, STÉPHANE MINVIELLE, LOÏC CAMPION, WILFRIED GOURAUD, MARIO CAMPONE, RÉGINE DÉPORTE-FÉTY, YVES-JEAN BIGNON, FRÉDÉRIQUE PENAULT-LLORCA, PASCAL JÉZÉQUEL
Format Journal Article
LanguageEnglish
Published International Institute of Anticancer Research 01.03.2006
Online AccessGet full text

Cover

More Information
Summary:Background: In breast cancer treatment, FEC100 (fluorouracil, epirubicin and cyclophosphamide) chemotherapy delivered in a neoadjuvant setting is still applied empirically to all patients. The aim of this study was to establish a multigene classifier of sensitivity to neoadjuvant FEC100. Materials and Methods: cDNA nylon microarrays, containing 15,000 genes, were used to analyze the gene expression profiles of tumour biopsies collected before chemotherapy: 8 were typed as pathological complete responders and 8 as non-responders according to their histological and clinical responses. Results: A classifier was generated by means of Linear Discriminant Analysis and was evaluated by leave-one-out cross-validation. The difference of expression of the NDUFB5 gene (NADH dehydrogenase 1 beta subcomplex, 5), the best discriminating gene, was verified using RT-PCR. Conclusion: This preliminary work requires further investigations, especially in terms of larger cohorts, before the results can be transferred to clinical practice.
ISSN:1109-6535